Questions? We're here to help. 1 (800) 489-7800

Cervical Cancer


According to the American Cancer Society, cervical cancer was one of the most common causes of cancer death for women in America. But over the last 30 years, the cervical cancer death rate has decreased by more than 50 percent due to the increased use of the Pap test. If cervical cancer is detected early, it is one of the most successfully treated cancers. Women, take charge of your health, and talk to your doctor about screening recommendations. Early detection saves lives!


At the Breast & GYN Cancer Pavilion, a unique facility dedicated solely to treating women with breast and gynecologic cancer, Mary Bird Perkins – Our Lady of the Lake Cancer Center and Woman’s Hospital are working side-by-side. With the most experienced doctors and teams, surgical procedures, breakthrough treatments and national clinical trials, we provide everything needed for your care and life beyond your diagnosis.

January is cervical cancer awareness month


Risk factors for cervical cancer include infection by the human papilloma virus (HPV), smoking and family history. Women at high risk might include those with HIV infection, organ transplant or exposure to the drug DES. For questions about risk factors, talk with your doctor.


Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after vaginal sex, bleeding after menopause, bleeding and spotting between periods, and having (menstrual) periods that are longer or heavier than usual. Bleeding after douching or after a pelvic exam may also occur. Other symptoms may include pain during sex or an unusual discharge from the vagina. The discharge may contain some blood and may occur between your periods or after menopause.




All women should begin cervical cancer screening at age 21. Women between the ages of 21 and 29 should have a Pap test every 3 years. Usually, they do not be tested for HPV unless it is needed after an abnormal Pap test result. Women between the ages of 30 and 65 should have both a Pap test and an HPV test every 5 years. This is the preferred approach, but it is also OK to have a Pap test alone every 3 years.

Women who are at high risk for cervical cancer may need to be screened more often. They should talk with their doctor or nurse.



Clinical trials are research studies that involve human beings in order to test new ways to prevent, detect, diagnose or treat diseases. A drug must be part of a clinical trial before the FDA will approve it to be put on the market. Oncology clinical trials are conducted in order to test new drugs or a new combination of drug treatments, new surgery and radiation therapies and new medical devices.

Every cancer center patient is evaluated for participation in a clinical trial. Those who meet the criteria to participate in clinical research receive a standard of care treatment, but with the added benefit of a trial that may enhance their outcomes.

If interested in volunteering to participate in a clinical research trial, or if you have concerns about the conduct of clinical research, please contact the Clinical Research office at (225) 215-1353, or by email at

Trial Number: 24607 DUETTE

Title: A Phase II Randomized, Multi-Center Study to investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer, who Have Previously Received PARP Inhibitor Maintenance Treatment

Purpose: To investigate the effectiveness and tolerability of a second maintenance treatment in participants with platinum-sensitivity relapsed (PSR) epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (complete response [CR] or partial response [PR]) or stable disease (SD) from further platinum-based chemotherapy.

Physicians: Dr. Patricia Braly

Offered in: Covington

Trial Number: NRG GY018

Title: A Phase III Randomized, Placebo – Controlled Study of Pembrolizumab (MK-3475, NSC #776864) IN Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVE or Recurrent Endometrial Cancer

Purpose: This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent).

Physicians: Drs. David S. HansonSobia OzairKellie D. SchmeeckleDerrick W. SpellLauren Zatarain.

Offered in: Baton Rouge (Breast & GYN Cancer Pavilion)

Trial NumberNRG GY005

Title: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

Purpose: This trial studies how well Cediranib maleate and Olaparib work when given together or separately. Further comparing them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory).

Physicians: Drs. David S. HansonSobia OzairKellie D. SchmeeckleDerrick W. SpellLauren Zatarain; Patricia Braly

Offered in: Baton Rouge (Breast & GYN Cancer Pavilion), Covington